Janssen Search
Search results
Megha Reddy
MEGHA REDDY HEAD OF STRATEGY WORLD WITHOUT DISEASE ACCELERATOR As Head of Strategy for the World Without Disease Accelerator (WWDA), Megha leads the overall WWDA strategic planning, including the development of short- and long-term goals and objectives. ...
Tom Cavanaugh
TOM CAVANAUGH COMPANY GROUP CHAIRMAN NORTH AMERICA Tom Cavanaugh is Company Group Chairman, North America, Tom is a member of the Innovative Medicine Pharmaceuticals Group Operating Committee and responsible for leading our efforts to transform the health ...
Green Chemistry and Technology
Green Chemistry and Technology Our R&D teams continue to integrate principles of green chemistry and engineering to develop our medicines. A few examples include: For application in our late-stage product portfolio, we achieved process intensification ...
World Without Disease Accelerator Leadership
Leadership The WWDA leadership team, a diverse group of experts globally situated within Janssen and Johnson & Johnson Innovation locations, is united by one vision: to lead a new paradigm in health care through the interception of disease. Article ...
Fighting Multi-Drug Resistant Tuberculosis
Fighting Multi-Drug Resistant Tuberculosis (MDR-TB) Creating Long-Term, Sustainable Solutions More than 480,000 new cases of multi-drug resistant tuberculosis (MDR-TB) were reported worldwide in 2013, and only 20 percent of MDR-TB patients were enrolled ...
The Importance Of Workplace Diversity
Why Having a Diverse and Harmonious Workplace is More Important Than Ever As the Asia Pacific region continues to accelerate economically and evolve demographically, organizations are increasingly monitoring whether their workforces reflect the diverse ...
Janssen at CROI: Harnessing Innovation in HIV Therapeutics
Janssen at CROI: Harnessing Innovation in HIV Therapeutics HIV remains one the biggest public health threats of our time. It is estimated that 36.7 million people are currently living with HIV globally, with at least 1.8 million more becoming newly ...
One Size Fits Not: The "E's" of Accessible Transformational Medicines for Those Living with Rare Diseases
One Size Fits Not: The "E's" of Accessible Transformational Medicines for Those Living with Rare Diseases Did you know that approximately 300 million people worldwide are living with one of the 6,000+ rare diseases, most of which have no ...
About Our Global Public Health Initiative
Janssen’s Commitment to Global Public Health At Janssen, the Pharmaceutical Companies of Johnson & Johnson, we have a single overarching mission: to address and solve the most important unmet medical needs of our time. Janssen aims to build on our ...
Ann Beliën, Ph.D.
Ann Beliën contributes to development of the Janssen Prevention Center’s discovery portfolio in two main ways. In her Management Team role as Head of Strategy, she is responsible for providing the Global Head of the Janssen Prevention Center with a clear ...